TY - JOUR
T1 - Interventions to increase use of nicotine gum
T2 - A randomized, controlled, single-blind trial
AU - Mooney, Marc
AU - Babb, David
AU - Jensen, Joni A
AU - Hatsukami, Dorothy
PY - 2005/8
Y1 - 2005/8
N2 - Medication noncompliance with smoking cessation pharmacotherapies is a significant problem in both research and clinical settings. This randomized, controlled, single-blind study compared three single-session psychological interventions to increase use of nicotine gum during a 15-day treatment period. A total of 97 adult smokers were randomized to receive standard treatment (ST, n=31), brief feedback (BF, n=32) plus ST, or contingency management (CM; i.e., payment for chewing at least 12 pieces/day on 10 of 15 intervention days, n=34) plus ST and BF. Only the CM condition led to significantly greater average daily gum use (pieces/day: ST, 6.17; BF, 7.81; CM, 10.17 [p values <.05]) and higher rates of compliance (ST, 13.6%; BF, 25.2%; CM, 65.6% [p values <.001]). No differences were observed in smoking abstinence, nicotine withdrawal, or urinary cotinine as a function of treatment. Implications of the present findings are discussed, including application to clinical trials and extension to real-world use of nicotine gum.
AB - Medication noncompliance with smoking cessation pharmacotherapies is a significant problem in both research and clinical settings. This randomized, controlled, single-blind study compared three single-session psychological interventions to increase use of nicotine gum during a 15-day treatment period. A total of 97 adult smokers were randomized to receive standard treatment (ST, n=31), brief feedback (BF, n=32) plus ST, or contingency management (CM; i.e., payment for chewing at least 12 pieces/day on 10 of 15 intervention days, n=34) plus ST and BF. Only the CM condition led to significantly greater average daily gum use (pieces/day: ST, 6.17; BF, 7.81; CM, 10.17 [p values <.05]) and higher rates of compliance (ST, 13.6%; BF, 25.2%; CM, 65.6% [p values <.001]). No differences were observed in smoking abstinence, nicotine withdrawal, or urinary cotinine as a function of treatment. Implications of the present findings are discussed, including application to clinical trials and extension to real-world use of nicotine gum.
UR - http://www.scopus.com/inward/record.url?scp=27744518077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744518077&partnerID=8YFLogxK
U2 - 10.1080/14622200500185637
DO - 10.1080/14622200500185637
M3 - Article
C2 - 16085528
AN - SCOPUS:27744518077
SN - 1462-2203
VL - 7
SP - 565
EP - 580
JO - Nicotine and Tobacco Research
JF - Nicotine and Tobacco Research
IS - 4
ER -